Tumor-associated macrophages (TAMs) can inhibit tumor immune efficacy. Colony stimulating factor 1 receptor (CSF-1R)/CSF-1 pathway involved in regulating the function of TAMs. CSF-1R is a tyrosine kinase transmembrane receptor, also a member of the growth factor CSF-1/platelet derived growth factor (PDGF) receptor family.

Proliferating Cell Nuclear Antigen (PCNA) is a protein present in all eukaryotic cells that plays a crucial role in DNA synthesis and repair.

Moderna's R&D pipeline covers multiple areas, with major research areas including COVID-19 vaccines, influenza vaccines, preventive vaccines, systemic secretion and cell surface treatments; exploratory areas include tumor vaccines, local regeneration therapies, cell therapies and more.

These findings suggest that Puma inhibitors may have therapeutic potential for the treatment of these disorders.

On August 1, 2023, AstraZeneca has reached an agreement to pay $510 million to BMS to resolve patent lawsuit over its PD-L1 mAb Imfinzi (Durvalumab) and CTLA-4 mAb Imjudo (Tremelimumab).

On August 1, 2023, MyMD Pharmaceuticals announced that the oral Tumor Necrosis Factor-α (TNF-α) inhibitor MYMD-1 achieved statistically significant positive results in a Phase 2 randomized clinical trial (NCT05283486).

On July 31, 2023, Sumitomo Dainippon Pharma and Otsuka Pharmaceutical jointly announced that their two Phase III studies, DIAMOND 1 and DIAMOND 2, for ulotaront (SEP-363856) in the treatment of acute schizophrenia did not meet the primary endpoints.

In a recent study, researchers from Stanford University in the US have made a significant discovery in the field of cancer treatment.

On August 1, 2023, the official website of the Chinese Drug Evaluation Center (CDE) shows that the new drug application (NDA) for Zolbetuximab injection developed by Astellas has been accepted for review.

Dostarlimab is the first immunotherapy approved by the FDA to be used in combination with chemotherapy for the first-line treatment of this patient population.

A new study published in the journal Gut has revealed a potential new target on TAMs for cancer immunotherapy.

Checkpoint Therapeutics announced the long-term data obtained in its key study on the PD-L1 inhibitor cosibelimab for the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma (cSCC).